Navidea Biopharmaceuticals, Inc. (NO1A.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 09:33AM CEST. Market open.
| Previous close | 0.0665 |
| Open | 0.0665 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0665 - 0.0665 |
| 52-week range | 0.0320 - 0.3020 |
| Volume | |
| Avg. volume | 560 |
| Market cap | 6.656M |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings date | 21 June 2024 - 22 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.50 |
Business WireNavidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
COLUMBUS, Ohio, June 20, 2024--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.
Business WireNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
COLUMBUS, Ohio, January 27, 2024--Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
Business WireNavidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
DUBLIN, Ohio, December 01, 2023--Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
© 2024 Yahoo. All rights reserved.